The report provides comprehensive information on the
therapeutics under development for Anthrax, complete with analysis by stage of
development, drug target, mechanism of action (MoA), route of administration
(RoA) and molecule type. The report also covers the descriptive pharmacological
action of the therapeutics, its complete research and development history and
latest news and press releases. Additionally, the report provides an overview
of key players involved in therapeutic development for Anthrax and features
dormant and discontinued projects.
Get Sample Report @ https://www.wiseguyreports.com/sample-request/619279-anthrax-pipeline-review-h2-2016
Report features investigational drugs from across globe
covering over 20 therapy areas and nearly 3,000 indications. Drug profiles
featured in the report undergoes periodic review following a stringent set of
processes to ensure that all the profiles are updated with the latest set of
information. Additionally, various dynamic tracking processes ensure that the
most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging
players in the market and their portfolios, enhances decision making
capabilities and helps to create effective counter strategies to gain
competitive advantage.
Scope
- The report provides a snapshot of the global therapeutic
landscape of Anthrax
- The report reviews pipeline therapeutics for Anthrax by
companies and universities/research institutes based on information derived
from company and industry-specific sources
- The report covers pipeline products based on various
stages of development ranging from pre-registration till discovery and
undisclosed stages
- The report features descriptive drug profiles for the
pipeline products which includes, product description, descriptive MoA, R&D
brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Anthrax
therapeutics and enlists all their major and minor projects
- The report assesses Anthrax therapeutics based on drug
target, mechanism of action (MoA), route of administration (RoA) and molecule
type
- The report summarizes all the dormant and discontinued
pipeline projects
- The report reviews latest news related to pipeline
therapeutics for Anthrax
Reasons to buy
- Gain strategically significant competitor information,
analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product
portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of
therapeutics under development for Anthrax
- Identify potential new clients or partners in the target
demographic
- Develop strategic initiatives by understanding the focus
areas of leading companies
- Plan mergers and acquisitions effectively by identifying
key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by
understanding Anthrax pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing
strategies by identifying prospective partners with the most attractive
projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying
discontinued projects and understanding the factors that drove them from
pipeline
Table of
Contents
Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Anthrax Overview 8
Therapeutics Development 9
Pipeline Products for Anthrax - Overview 9
Pipeline Products for Anthrax - Comparative Analysis 10
Anthrax - Therapeutics under Development by Companies 11
Anthrax - Therapeutics under Investigation by
Universities/Institutes 13
Anthrax - Pipeline Products Glance 14
Late Stage Products 14
Clinical Stage Products 15
Early Stage Products 16
Anthrax - Products under Development by Companies 17
Anthrax - Products under Investigation by
Universities/Institutes 20
Anthrax - Companies Involved in Therapeutics Development 21
Aduro BioTech, Inc. 21
Altimmune, Inc. 22
Aphios Corporation 23
Aradigm Corporation 24
AtralCipan 25
Cellceutix Corporation 26
ContraFect Corporation 27
Dynavax Technologies Corporation 28
Emergent BioSolutions Inc. 29
GlaxoSmithKline Plc 30
Green Cross Corporation 31
Contact Info:
NORAH TRENT
Partner Relations
& Marketing Manager
Ph:
+1-646-845-9349 (US)
Ph: +44 208 133 9349 (UK)
Get
in touch:
LinkedIn:
www.linkedin.com/company/4828928
Twitter:
https://twitter.com/WiseGuyReports
No comments:
Post a Comment